Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

bidly with dementia and excessive day time sleepiness. We believe that ITI-002 will be uniquely effective in treating these non-motor complications that are associated with Parkinson's disease."

ABOUT ITI-002

ITI-002 is a unique, orally available, investigational drug being developed for the treatment of motor and non-motor impairments accompanying Parkinson's disease and other neurologic and neuropsychiatric disorders, including schizophrenia and Alzheimer's disease.

ITI-002 potently inhibits the PDE1 enzyme in a competitive manner with sub-nanomolar affinity for this subfamily. This compound is very selective for the PDE1 subfamily relative to other PDE subfamilies. ITI-002 has no significant off target activities at other enzymes, receptor or ion channels.

PDE Type I – PDE enzymes hydrolyze and inactivate cyclic nucleotides (cAMP and cGMP) in the brain.  Eleven classes of PDE enzymes with distinct tissue distributions, cyclic nucleotide selectivity, and regulatory factors are known.  The PDE1 family of enzymes, including PDE1A, PDE1B, and PDE1C isoforms, are calcium/calmodulin-dependent, dual-function (cAMP/cGMP) PDEs that are expressed at high levels in mammalian brain. This enzyme subfamily has little influence on basal nucleotide activity and only becomes active under stimulated conditions.  This "on demand" character distinguishes PDE1 from all other PDE family members. PDE1 is enriched in the striatal medium spiny neurons that lose dopamine input in Parkinson's disease and controls the responsiveness of striatal neurons to dopamine. Intra-Cellular Therapies has shown that orally available, small molecule inhibitors of PDE1 restore dopamine signaling in striatal neurons and potentiate the level of motor correction in Parkinson's disease.

About Parkinson's Disease - Parkinson's disease is a progressive, neurodegenerative disease. The prevalence of Parkinson's disease increases with a
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... April 02, 2015 One of ... to avoid false negative results. MultiGEN Diagnostics, LLC ... Laboratory Services, LLC (PCLS), has developed a novel ... false negatives, while at the same time maintains ... unique combination is expected to improve the quality ...
(Date:4/1/2015)... , April 1, 2015  Adaptive Biotechnologies ... The Lancet Oncology showing that ... company,s next-generation sequencing-based minimal residual disease (MRD) detection ... MRD test) accurately identifies patients with diffuse large ... relapse after initial treatment, usually several months before ...
(Date:4/1/2015)... Clara, CA (PRWEB) April 01, 2015 ... Force Microscopes (AFM) was selected to receive the ... The New Economy Magazine.    Park NX10 is the premium ... XY and Z scanner linearity, closed-loop detector noise, ... feature, SmartSca n, which allows images ...
(Date:4/1/2015)... 1, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... pleased to announce that Biohaven Pharmaceutical Holding Company ... entered into an agreement with inVentiv Health for ... with their lead compound (BHV-0223). ... of clinical stage neuroscience compounds targeting the glutamatergic ...
Breaking Biology Technology:MultiGEN Diagnostics, LLC Announces the Use of IC-Code™ Technology to Eliminate False Negatives in Molecular Diagnosis. 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3
... - Attendees at The 18th CPM Resource ... Era , The healthcare industry ... billions allotted for healthcare information technology transformation in,the American ... according to observations shared at the 18th CPM Resource ...
... In spite of continued growth in computational resources ... surrogate to physical reality still faces conceptual and ... of physical reality itself, under conditions of incomplete ... fluctuations. The quantification of this uncertainty has, in ...
... Acquisition LLC (the "Purchaser"), an affiliate of Biotechnology Value Fund ... purchase all of the outstanding shares of Avigen, Inc. (Nasdaq: ... today that it has extended the expiration date for the ... Friday, April 3, 2009. The tender offer was previously set ...
Cached Biology Technology:Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 2Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 3Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 4Opportunities and challenges in uncertainty quantification for complex interacting systems 2BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009 2BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009 3
(Date:3/12/2015)... -- The mascots of the Atlantic Coast Conference spent ... Forest Baptist Medical Center. They stopped by as part ... Basketball Tournament. Young patients enjoyed bonding with their favorite ... Brenner Children,s Hospital is the pediatric arm ... hospital in northwest North Carolina ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... Colo. , March 10, 2015 ... Flight "Personalized Medicine in Human Space ... and Thomas J. Goodwin , Ph.D. was recently ... of the past two years. Specifically, "Personalized ... most downloaded scientific papers published in 2013 and 2014 ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... 30,000 still images and video, as well as local ... Encyclopedia of Life via new tools that let the ... science collaboration of unprecedented scale. Experts and citizen ... encyclopedia, which dedicates a Web page to each known ...
... , , , ... biometric technology research and development firm, announced today that GHG ... provide their customers with M2SYS, Bio-SnapON(TM) biometric software solution. , ... biometric recognition capabilities to their web-based employee time tracking software, ...
... FORT WORTH, Texas, Aug. 4 Of the 600,000-800,000 people ... is estimated that by 2010, human trafficking will be the No. 1 ... Ph.D., professor and chairman of the department of forensic and investigative Genetics ... at the University of North Texas (UNT) Health Science ...
Cached Biology News:Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 2Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 3Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 4Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 5Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 6Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 7M2SYS Biometric Software Solution Selected By GHG Corporation 2DNA Helps Reunite Children With Their Families 2DNA Helps Reunite Children With Their Families 3
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... Hinge Region By immunoblotting the antibody reacts ... reacts with free MMP-2 or MMP-2 bound ... aqueous glycerol solution Solution in 0.01 ... 50% glycerol and 15 mM sodium azide. ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
Biology Products: